Open AccessCD56–chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma
Author(s) -
Chuhan Jiang,
Wen Zhao,
Maoquan Qin,
Mei Jin,
LungJi Chang,
Xiaoli Ma
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000017572
Subject(s) - medicine , rhabdomyosarcoma , chimeric antigen receptor , refractory (planetary science) , embryonal rhabdomyosarcoma , malignancy , cytokine release syndrome , soft tissue sarcoma , hematopoietic stem cell transplantation , chemotherapy , radiation therapy , antigen , oncology , surgery , sarcoma , immunotherapy , transplantation , immunology , soft tissue , pathology , cancer , physics , astrobiology
Rationale: Rhabdomyosarcoma (RMS) is a common soft tissue sarcoma in children with high malignancy. The prognosis of refractory recurrent RMS is extremely poor, and the 5-year survival rate is less than 20%. Patient concerns: We reported a 2-year-old male patient with RMS who underwent 3 operations and 2 recurrences while being treated with regular multidisciplinary therapy. Diagnoses: A diagnosis of embryonal rhabdomyosarcoma with primary bladder (IIIa, TNM stage 2, and medium risk group) was made. Interventions: After repeated recurrence, the patient was treated with chimeric antigen receptor T (CAR-T) cells, which had a safety mechanism and specifically bound the CD56 antigen in the fourth generation. Outcomes: The process of CAR-T cell transfusion was smooth, and there were no significant cytokine release syndrome manifestations after reinfusion. The patient was in complete remission at last follow-up visit after 3.5 years. Conclusion: CD56–CAR-T cell therapy is a safe and effective approach and may be an option for children with solid tumors who are nonresponsive to conventional radiotherapy and chemotherapy, or are unsuitable for hematopoietic stem cell transplantation.